Article
Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.
Blood - 23 Mar 2017
Yeh Paul, Dickinson Michael, Ftouni Sarah, Hunter Tane, Sinha Devbarna, Wong Stephen Q, Agarwal Rishu, Vedururu Ravikiran, Doig Kenneth, Fong Chun Yew, Blombery Piers, Westerman David, Dawson Mark A, Dawson Sarah-Jane
Abstract excerpt
The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on bone marrow morphology, which is associated with substantial interobserver variability. Although azacitidine is the mainstay of treatment in MDS, only half of all patients respond. Therefore, there is an urgent need for improved modalities for the diagnosis and monitoring of MDSs. The majority of MDS patients have either clonal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.